These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 14989224)

  • 21. Comment on: "FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging, version 1.0".
    Saboury B; Torigian DA; Alavi A
    Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1430-1; author reply 1432-3. PubMed ID: 20503048
    [No Abstract]   [Full Text] [Related]  

  • 22. The good laboratory practice and good clinical practice requirements for the production of radiopharmaceuticals in clinical research.
    De Vos FJ; De Decker M; Dierckx RA
    Nucl Med Commun; 2005 Jul; 26(7):575-9. PubMed ID: 15942476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Procedure guidelines for radionuclide myocardial perfusion imaging.
    Anagnostopoulos C; Harbinson M; Kelion A; Kundley K; Loong CY; Notghi A; Reyes E; Tindale W; Underwood SR
    Nucl Med Commun; 2003 Oct; 24(10):1105-19. PubMed ID: 14508167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guidelines for radioiodinated MIBG scintigraphy in children.
    Olivier P; Colarinha P; Fettich J; Fischer S; Frökier J; Giammarile F; Gordon I; Hahn K; Kabasakal L; Mann M; Mitjavila M; Piepsz A; Porn U; Sixt R; van Velzen J
    Eur J Nucl Med Mol Imaging; 2003 May; 30(5):B45-50. PubMed ID: 12658506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Guidelines for the measurement of glomerular filtration rate using plasma sampling.
    Fleming JS; Zivanovic MA; Blake GM; Burniston M; Cosgriff PS;
    Nucl Med Commun; 2004 Aug; 25(8):759-69. PubMed ID: 15266169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Good clinical practice: historical background and key aspects.
    Otte A; Maier-Lenz H; Dierckx RA
    Nucl Med Commun; 2005 Jul; 26(7):563-74. PubMed ID: 15942475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Position Statement on Emergency Medicine Definitions from the Canadian Association of Emergency Physicians.
    McEwen J; Borreman S; Caudle J; Chan T; Chochinov A; Christenson J; Currie T; Fuller B; Howlett M; Koczerginski J; Kuuskne M; Lim RK; McLeod B; Pageau P; Paraskevopoulos C; Rosenblum R; Stiell IG
    CJEM; 2018 Jul; 20(4):501-506. PubMed ID: 30033894
    [No Abstract]   [Full Text] [Related]  

  • 28. [New dietary guidelines before FDG-PET, or how to simply improve validity].
    Margery J; Bonardel G; Vaylet F; Guigay J; Gaillard JF; L'Her P
    Rev Pneumol Clin; 2002 Dec; 58(6 Pt 1):359. PubMed ID: 12545136
    [No Abstract]   [Full Text] [Related]  

  • 29. Accurate dosimetry: an essential step towards good clinical practice in nuclear medicine.
    Bacher K; Thierens HM
    Nucl Med Commun; 2005 Jul; 26(7):581-6. PubMed ID: 15942477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Draft guidelines for radiopharmacy.
    EANM
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):BP63-72. PubMed ID: 14552340
    [No Abstract]   [Full Text] [Related]  

  • 31. Is whole-body FDG-PET valuable for health screening? Against.
    Weckesser M; Schober O
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):342-3. PubMed ID: 15726351
    [No Abstract]   [Full Text] [Related]  

  • 32. European Association of Nuclear Medicine procedure guidelines for brain perfusion SPET using (99m)Tc-labelled radiopharmaceuticals.
    Tatsch K; Asenbaum S; Bartenstein P; Catafau A; Halldin C; Pilowsky LS; Pupi A;
    Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):BP36-42. PubMed ID: 12436497
    [No Abstract]   [Full Text] [Related]  

  • 33. Guest editorial: the conception of FDG-PET imaging.
    Alavi A; Reivich M
    Semin Nucl Med; 2002 Jan; 32(1):2-5. PubMed ID: 11839067
    [No Abstract]   [Full Text] [Related]  

  • 34. 18F-FDG PET in candidates for radiation therapy: is it important and how do we validate its impact?
    Hicks RJ; Mac Manus MP
    J Nucl Med; 2003 Jan; 44(1):30-2. PubMed ID: 12515873
    [No Abstract]   [Full Text] [Related]  

  • 35. [Update of 'standards, options and recommendations' for FDG-PET in breast and gynaecological cancers].
    Talbot JN; Grahek D
    Gynecol Obstet Fertil; 2006 May; 34(5):434-6. PubMed ID: 16677841
    [No Abstract]   [Full Text] [Related]  

  • 36. [Standards, Options and Recommendations 2002 for the use of Positron Emission Tomography with [18F]-FDG (PET-FDG in cancerology (integral connection].
    Bourguet P;
    Bull Cancer; 2003 Feb; 90 Spec No():S5-17. PubMed ID: 12739332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ESC Committee for Practice Guidelines: providing knowledge to everyday clinical practice.
    Windecker S
    Cardiovasc Res; 2020 Sep; 116(11):e146-e148. PubMed ID: 32845966
    [No Abstract]   [Full Text] [Related]  

  • 38. Is whole-body FDG-PET valuable for health screening? For.
    Ide M; Suzuki Y
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):339-41. PubMed ID: 15726352
    [No Abstract]   [Full Text] [Related]  

  • 39. Measurement of tumor response using [18F]-2-fluoro-2-deoxy-D-glucose and positron-emission tomography.
    Lammertsma AA
    J Clin Pharmacol; 2001 Jul; 41(S7):104S-106S. PubMed ID: 11452713
    [No Abstract]   [Full Text] [Related]  

  • 40. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Technical bases and regulatory principles].
    Bourguet P;
    Bull Cancer; 2003 Feb; 90 Spec No():S18-22. PubMed ID: 12739333
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.